Vaccine chống lại các chất gây nghiện

Bonese KF, Wainer BH, Fitch FW, et al. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974; 252: 708–10 Carroll FI, Howell LL, Kuhar MJ. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 1999; 42: 2721–36 Akbarzadeh A, Mehraby M, Zarbakhsh M, et al. Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl Biochem 1999; 30: 139–45 Morell V. Enzyme may blunt cocaine’s action. Science 1993; 259: 1828 Landry DW, Zhao K, Yang GX, et al. Antibody-catalyzed degradation of cocaine. Science 1993; 259: 1899–901 Yang G, Chun J, Arakawa-Uramoto H, et al. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J Am Chem Soc 1996; 118: 5881–90 Mets B, Winger G, Cabrera C, et al. A catalytic antibody against cocaine prevents cocaine’s reinforcing and toxic effects in rats. Proc Natl Acad Sci U S A 1998; 95: 10176–81 Baird TJ, Deng SX, Landry DW, et al. Natural and artificial enzymes against cocaine. I: Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J Pharmacol Exp Ther 2000; 295: 1127–34 Basmadjian GP, Singh S, Sastrodjojo B, et al. Generation of polyclonal catalytic antibodies against cocaine using transition state analogs of cocaine conjugated to diptheria toxoid. Chem Pharm Bull (Tokyo) 1995; 43: 1902–11 Cashman JR, Berkman CE, Underiner GE. Catalytic antibodies that hydrolyze (−): cocaine obtained by a high-throughput procedure. J Pharmacol Exp Ther 2000 293: 952–61 Bagasra O, Forman LJ, Howeedy A, et al. A potential vaccine for cocaine abuse prophylaxis. Immmunopharmacology 1992; 23: 173–9 Carrera MRA, Ashley JA, Parsons LH, et al. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995; 378: 727–30 Carrera MRA, Ashley JA, Zhou B, et al. Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci U S A 2000; 97: 6202–6 Carrera MR, Ashley JA, Wirsching P, et al. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci U S A 2001; 98: 1988–92 Ettinger RH, Ettinger WF, Harless WE. Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol Biochem Behav 1997; 58: 215–20 Johnson MW, Ettinger RH. Active cocaine immunization attenuates the discriminative properties of cocaine. Exp Clin Psychopharmacol 2000; 8: 163–7 Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2: 1129–32 Evans SM, Cone EJ, Henning field JE. Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects. J Pharmacol Exp Ther 1996; 279: 1345–56 Kantak KM, Collins SL, Lipman EG, et al. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 2000; 148: 251–62 Kantak KM, Collins SL, Bond J, et al. Time course of changes in cocaine self-administration behavior during immunization with the cocaine vaccine IPC-1010. Psychopharmacology 2001; 153: 334–40 Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20: 1196–204 TA-CD. Available from URL: http://www.xenova.co.uk/dc_ta_cd.html [Accessed 2002 Jan 15] Anti-cocaine addiction vaccine released from clinical hold phase Ha study results announced [online]. Available from URL: http://www.xenova.co.uk/PressReleases/pr_20010709_01.html [Accessed 2002 Jan 15] Schabacker DS, Kirschbaum KS, Segre M. Exploring the feasibility of anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta anti-idiotypic antibodies. Immunology 2000; 100: 48–56 Washton AM, Stone-Washton N. Abstinence and relapse in outpatient cocaine addicts. J Psychoactive Drugs 1990; 22: 135–47 Song N, Parker RB, Laizure SC. Cocaethylene formation in rat, dog and human hepatic microsomes. Life Sci 1999; 64: 2101–8 McCance-Katz EF, Kosten TR, Jatlow P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone: a multiple-dose study. Biol Psychiatry 1998; 44: 250–9 Raven MA, Necessary BD, Danluck D, et al. Comparison of the reinforcing and anxiolytic effects of intravenous cocaine and cocaethylene. Exp Clin Psychopharmacol 2000; 8: 117–24 McKay JR, Alterman AI, Rutherford MJ, et al. The relationship of alcohol use to cocaine relapse in cocaine dependent patients in an aftercare study. J Stud Alcohol 1999; 60: 176–80 Bordnick PS, Schmitz JM. Cocaine craving: an evaluation across treatment phases. J Subst Abuse 1998; 10: 9–17 Kuhar MJ, Carroll FI, Bharat N, et al. Anticocaine catalytic antibodies have no affinity for RTI compounds: implications for treatment. Synapse 2001; 41: 176–8 Hieda Y, Keyler DE, Vandevoort JT, et al. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997; 283: 1076–81 Benowitz NL, Hall SM, Herning RI, et al. Smokers of low yield cigarettes do not consume less nicotine. N Engl J Med 1983; 309: 139–42 Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993; 33: 23–9 Hieda Y, Keyler DE, Vandevoort JT, et al. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology 1999; 143: 150–7 Keyler DE, Hieda Y, Peter J, et al. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res 1999; 1: 241–9 Hieda Y, Keyler DE, Ennifar S, et al. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000; 22: 809–19 Pentel PR, Malin DH, Ennifar S, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65: 191–8 Malin DH, Lake JR, Lin A, et al. Passive immunization against nicotine prevents alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001; 68: 87–92 Tuncok Y, Hieda Y, Keyler DE, et al. Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Exp Clin Psychopharmacol 2001; 9: 228–34 Nabi Biopharmaceuticals reports encouraging preliminary results of NicVAX™ clinical trial [online]. Available from URL: http://www.nabi.com/releases/100302.html [Accessed 2002 Dec 30] Successful results of phase I trial for TA-NIC: first evaluation of anti-nicotine vaccine in man. Available from URL: http://www.xenova.co.uk/pressreleases/pr_20020614_01.html [Accessed 2002 Dec 30] Kasaian M. Development of a vaccine for treatment of nicotine dependence [abstract]. NIDA Symposium on Peripheral Blockers as Treatments for Substance Abuse and Dependence. 1998 Apr 27–28. Available from URL: http://165.112.78.61/meetsum/peripheral/index.html (Accessed 2002 Jan 15) de Villiers S, Lindblom N, Kalayanov G, et al. Active immunisation against nicotine can suppress the nicotine-induced stimulation of brain dopaminergic reward pathways [abstract 192.12]. Soc Neurosci 2000; 26 (Pt 1): 529 Isomura S, Wirsching P, Jandra KD. An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J Org Chem 2001; 66: 4115–21 West R, Hajek P, Nilsson F, et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacol 2001; 153: 225–30 Gross J, Stitzer ML. Nicotine replacement: ten-week effects on tobacco withdrawal symptoms. Psychopharmacol 1989; 98: 334–41 Owens SM, Mayersohn M. Phencyclidine-specific fab fragments alter phencyclidine disposition in dogs. Drug Metab Dispos 1986; 14: 52–8 McClurkan MB, Valentine JL, Arnold L, et al. Disposition of a monoclonal anti-phencyclidine fab fragment of immunoglob-ulin G in rats. J Pharmacol Exp Ther 1993; 266: 1439–45 Valentine JL, Arnold LW, Owens SM. Anti-phencyclidine monoclonal fab fragments markedly alter phencyclidine phar-macokinetics in rats. J Pharmacol Exp Ther 1994;269: 1079–85 Valentine JL, Mayersohn M, Wessinger WD, et al. Anti-phencyclidine monoclonal fab fragments reverse phencyclid-ine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther 1996; 278: 709–16 Valentine JL, Owens SM. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 1996; 278: 717–24 Proksch JW, Gentry WB, Owens SM. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 2000; 292: 831–7 Nature and effects of ketamine [online]. Available at URL: http://165.112.78.61/ResearchReports/hallucinogens/halluc4.html [Accessed 2002 Jan 15] Baldridge EB, Bessen HA. Phencyclidine. Emerg Med Clin North Am 1990; 8: 541–50 Curran HV, Monaghan L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001; 96: 749–60 Hardin JS, Wessinger WD, Proksch JW, et al. Pharmacodynamics of a monoclonal antiphencyclidine fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther 1998; 285: 1113–33 Murray JB. Psychophysiological aspects of amphetamine-methamphetamine abuse. J Psychol 1998; 132: 227–37 Byrnes-Blake KA, Carroll FI, Abraham P, et al. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int J Immunopharmacol 2001; 1: 329–38 Cohen PJ. Immunization for prevention and treatment of cocaine abuse: legal and ethical implications. Drug Alcohol Depend 1997; 48: 167–74